SCHEMBL15328107

SCHEMBL15328107

Cn1cc(C(N)=O)c(=O)c(-c2ccc(F)cc2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 7/20 0.50
AXL P30530 5/20 0.50
IKBKB O14920 5/20 0.41
CHUK O15111 3/20 0.41
PTGS1 P23219 1/20 0.38
ABCB1 P08183 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
MEN1 O00255 1/20 0.37
JAK2 O60674 1/20 0.37
EIF2AK2 P19525 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2591376 0.86 MET (0.48) METAXLSLC6A4SLC6A3CA1
SCHEMBL29812378 0.84 BCAT2 (0.51) METAXLIKBKBCHUKMEN1
Hydrochloric Acid SCHEMBL29812299 0.83 BCAT2 (0.50) METAXLIKBKBCHUKMEN1
SCHEMBL29812460 0.83 IKBKB (0.42) METAXLIKBKBCHUKPTGS1
SCHEMBL29811056 0.83 MAP4K4 (0.41) METAXLJAK2
Hydrochloric Acid SCHEMBL29811987 0.82 MAP4K4 (0.41) METAXLJAK2
SCHEMBL29811815 0.81 IKBKB (0.40) METAXLIKBKBCHUKPTGS1
SCHEMBL21776508 0.81 AXL (0.51) METAXLIKBKBCHUKPTGS1
Hydrochloric Acid SCHEMBL29812442 0.81 FGFR1 (0.46) CA12CA1CA2CA9
SCHEMBL29812120 0.81 MET (0.44) METAXLIKBKBCHUKPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 EP claimed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US claimed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US claimed
CN-116284043-A Tricyclic compound and medical application thereof 中国科学院上海药物研究所 2023-06-23 CN disclosed
CN-114787144-A Pyridone compounds and methods for modulating protein kinases 埃克塞里艾克西斯公司 2022-07-22 CN disclosed
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 EP disclosed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US disclosed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ING2, CDK2, MAP3K20 MET 1426/4885AXL 2249/4885IKBKB 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.